NCT06335836 The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
| NCT ID | NCT06335836 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Social Isolation |
| Study Type | OBSERVATIONAL |
| Enrollment | 209 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 209 participants in total. It began in 2024-03-01 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD; 2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation; 3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions; 4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.
Eligibility Criteria
Inclusion Criteria: * SCD 1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events; 2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met; 3. Selected candidates can sign the informed consent form themselves. Exclusion Criteria: * (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)
Contact & Investigator
Zhu Yi
STUDY CHAIR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06335836 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 85 Years, studying Social Isolation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06335836 currently recruiting?
Yes, NCT06335836 is actively recruiting participants. Contact the research team at ZhuYi1981@njmu.edu.cn for enrollment information.
Where is the NCT06335836 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06335836 clinical trial?
NCT06335836 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Zhu Yi at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 209 participants.